Microsoft word - 2010 - 10-6 final iroko investing group v2.docx

Iroko Pharmaceuticals Announces Financial Investment in New Product Development

PHILADELPHIA, PA, October 6, 2010 -
Iroko Pharmaceuticals, LLC, supported by a new investment group including a private equity fund
advised by Kew Capital LLP and Phoenix IP Ventures-III, LLC, will continue to market its well established
branded products Aldomet® (methyldopa), Indocin® (indomethacin) and the Canadian rights for the
antibiotic Vancocin® (vancomycin hydrochloride). In addition, the Company will focus significant new
investments into its advanced pipeline of pain management products. The Company is planning to make
strategic investments to grow its core business, including expanding use, gaining approval in additional
countries and/or acquiring new assets.
The additional funding invested into Iroko Pharmaceuticals will enable the Company to increase its focus
on the development of products formulated using its partner's, iCeutica Inc., proprietary SoluMatrix™
Platform for the creation of nano particle products. The United States Food and Drug Administration
(FDA) has allowed the Company's Investigational New Drug (IND) application for three development
programs. Two of these programs have successfully completed Phase II trials and are commencing their
Phase III trials in 2011.
Iroko President and CEO, John Vavricka, said "Today's announcement reflects our excitement
surrounding the new investment and revived focus on our near term pipeline and our existing revenue
generating products. This confirms our mission to deliver relevant and needed products to patients."
"We are very pleased to have a strong and aligned financial partner in Kew. This relationship will allow us
to deliver on the promise of Iroko Pharmaceuticals near term pipeline and focus on becoming a leading
specialty pharmaceutical company in the space of NSAID pain relief," stated Iroko Pharmaceutical's
Chairman and Senior Managing Partner of Phoenix IP Ventures, Osagie Imasogie. "These changes allow
us to drive forward the development of our nano particle formulations for the treatment of various acute
and chronic pain conditions while continuing to build our overall business."
About Iroko Pharmaceuticals, LLC: Iroko is a pharmaceutical company focused on specialty
therapeutic areas. The company acquires, develops and maximizes the potential of currently marketed
pharmaceutical products. Iroko increases the revenues of acquired products through focused selling and
marketing efforts and product life cycle management activities including development of relevant
formulations to improve patient treatment. Iroko currently has three products under development,
formulated by iCeutica's proprietary SoluMatrix™ Platform technology.
About Kew Capital LLP: Kew Capital is a private investment advisor formed in 2008. Kew advises on a
global portfolio of investments including bonds, listed and private equities, funds, listed and OTC
derivatives, structured products and real estate.

About Phoenix IP Ventures:
A fully integrated Private Equity and Venture Capital Fund which
specializes in life sciences, principally in the pharmaceutical sector. The Fund acquires intellectual
property protected assets that meet its criteria for value maximization. Phoenix IP Ventures works in
collaboration with major players in the financial community to scale its own proprietary investments in
transactions identified and managed by the Firm.
Lisa Gray, Phoenix IP Ventures


Microsoft word - anglicans ablaze prayer diary dec 2012 - feb 2013

Mon 04 Pray for more opportunities for local missions in order to Tues 26 Continue to pray for an outpouring of the Holy Spirit grow teams for missions outside our country SA Tues 05 Please pray for SOMA UK for mission teams to DR Wed 27 Pray for Mission Agencies in their endeavour to reach the lost. Pray for HAGGAI & OMF in training missionaries Wed 06 Pray for an incr

Microsoft word - coumadin_pm_e_10 mar 11_12 jul 12 v1_app_dist_cln.docx

PRODUCT MONOGRAPH PrCOUMADIN* Warfarin Sodium Tablets, Bristol-Myers Squibb Std., (crystalline) 1, 2, 2.5, 3, 4, 5, 6 and 10 mg Anticoagulant * TM of Bristol-Myers Squibb Pharma Company used under licence by Bristol-Myers Squibb Canada Control PRODUCT MONOGRAPH PrCOUMADIN* Warfarin Sodium Tablets, Bristol-Myers Squibb Std., (crystalline) THERAPEUTIC CLASSIFICATION

Copyright © 2018 Predicting Disease Pdf